BE563791A - - Google Patents
Info
- Publication number
- BE563791A BE563791A BE563791DA BE563791A BE 563791 A BE563791 A BE 563791A BE 563791D A BE563791D A BE 563791DA BE 563791 A BE563791 A BE 563791A
- Authority
- BE
- Belgium
- Prior art keywords
- histamine
- composition
- globulin
- gamma
- acid
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 39
- 229960001340 histamine Drugs 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 108010074605 gamma-Globulins Proteins 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 3
- 230000003603 histaminopectic Effects 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 229940102223 Injectable Solution Drugs 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 210000002966 Serum Anatomy 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- ZHLKXBJTJHRTTE-UHFFFAOYSA-N Chlorbenside Chemical compound C1=CC(Cl)=CC=C1CSC1=CC=C(Cl)C=C1 ZHLKXBJTJHRTTE-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 230000001387 anti-histamine Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940025708 Injectable Product Drugs 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 201000010000 agranulocytosis Diseases 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
<Desc/Clms Page number 1>
La présente invention est relative à la protection des organismes vivais, humains et animaux, contre l'action de l'histamine et les manifestations de l'allergie.
On sait que l'histamine provoque dans ces organis- mes des désordres qu'on s'est, jusqu'ici,efforcé de combattre par les antihistaminiques de synthèse. L'invention se propose non pas de lutter contre les désordres provoqués par l'histamine postérieu- rement à leur apparition, mais de prévenir ces désordres en commu- niquant à l'organisme une protection durable à l'égard de l'hista-"' mine.
Il a , en effet, été découvert,selon l'invention,
<Desc/Clms Page number 2>
que l'injection d'une composition contenant,, en proportions déter- minées,une gamma-globuline et de l'histamine conférait,,de manière inattandue, à l'organisme animal ou humain une protection à l'égard de l'histamine que ni l'un ni l'autre de ces deux constituants ne possède en propre. C'est ainsi qu'un sujet traité à l'aide d'une telle composition réagit moins à l'histamine qu'avant le traite- ment.
On se rendra aisément compte des avantages assurés par l'invention relativement à l'emploi, aujourd'hui classique, des agents antihistaminiques, étant donné qu'il vaut mieux prévenir que guérir. En outre, la protection assurée par la nouvelle compo- sition est durable, alors que l'administration des antihistamini- ques doit être répétée à chaque crise. Cette préparation est, de plus, dépourvue de toxicité, alors que les antihistaminiques sont souvent toxiques et c'est ainsi que certains,dérivés de l'aniline, ont provoqué des agranulocytoses mortelles.
L'invention a ainsi pour objet une composition des- tinée à créer chez l'homme et l'animal un état de protection à l'égard de l'histamine, cette composition étant remarquable notam- ment en ce qu'elle consiste en un mélange de gamma-globuline et d'histamine.
La gamma-globuline utilisée est extraite du sérum sanguin humain ou animal. Ce doit être bien entendu une prépara- tion purifiée correspondant à la fraction II de Cohn. Elle doit en outre être douée d'un pouvoir histaminopexique suffisant, su- , périeur ou égal à 25, la notion de pouvoir histaminopexique et la @ mesure de ce pouvoir étant précisées dans les communications sui- vantes de J. L. Parrot, D.A. Urquia et C, Laborde - C.R.Soc.Biol.
1951, 145, 885 et 1951, 145, 1045.
L'histamine utilisée doit être sous forme hydrosol ble et pour cela salifiée par un acide minéral ou organique, tel
<Desc/Clms Page number 3>
que par exemple l'acide chlorhydrique ou l'acide phosphorique.
La composition peut se présenter à l'état sec, les deux constituants ayant été mélangés à l'état sec ou ayant tous deux été dissous dans une solution saline, puis la solution évapo- rée à siccité. Il suffit de dissoudre ce produit sec dans de l'eau pour obtenir un produit injectable. La composition peut d'ailleurs être présentée directement sous forme de solution injectable, tel- le qu'une solution isotonique.
Pour que l'efficacité de la composition soit satis- faisante, les constituants doivent être en proportions relatives déterminées. C'est ainsi,en effet, que si 1 on trace une courbe donnant le degré de protection à l'égard de l'histamine de la com- position en fonction du rapport de l'histamine à la gamma-globuli ne, on obtient une courbe en cloche.
Cette courbe peut être établie en mesurant le pou- voir protecteur, à l'égard d'un aérosol d'histamine, conféré par l'injection au cobaye d'un cortain volume de cette préparation.
Cette action protectrice se traduit par l'allongement du temps de résistance de l'animal à l'aérosol. Elle est mesurable dans la se- maine qui suit l'injection, s'accroît par la, suite et se maintient pendant plusieurs mois.
En utilisant ce test , on peut établir les valeurs numériques suivantes :pour que la composition ait une activité satisfaisante, le rapport pondéral histamine (en dichlorhydrate) gamma-globuline doit être compris entre 0,003 x 10-3 et 0,05 x 10-3,.1 activité maximum étant observée pour une valeur de ce rapport égale à 0,0125 x 10-3. Ce maximum peut varier légèrement selon la dilution de la préparation réalisée. Si l'acide salifiant l'histamine est autre que l'acide chlorhydrique, il faut naturellement modifier le rapport précédent en fonction du poids moléculaire de cet au- tre acide.
<Desc/Clms Page number 4>
Bien entendu, l'invention n'est pas limitée aux modes de mise en oeuvre décrits qui n'ont été donnés qu'à titres d'exemples.
<Desc / Clms Page number 1>
The present invention relates to the protection of living organisms, human and animal, against the action of histamine and the manifestations of allergy.
We know that histamine causes disorders in these organisms which have hitherto been sought to combat with synthetic antihistamines. The invention does not propose to fight against the disorders caused by histamine after their appearance, but to prevent these disorders by communicating to the organism a lasting protection with regard to the histamine. 'mine.
It has, in fact, been discovered, according to the invention,
<Desc / Clms Page number 2>
that the injection of a composition containing, in determined proportions, a gamma-globulin and histamine conferred, in an unexpected way, on the animal or human organism a protection against histamine that neither of these two constituents has of its own. Thus, a subject treated with such a composition reacts less to histamine than before the treatment.
The advantages provided by the invention will easily be seen in relation to the use, now conventional, of antihistamine agents, given that prevention is better than cure. In addition, the protection provided by the new composition is long-lasting, while the administration of antihistamines must be repeated for each attack. This preparation is, moreover, devoid of toxicity, while antihistamines are often toxic and it is thus that some, derivatives of aniline, have caused fatal agranulocytosis.
The subject of the invention is thus a composition intended to create in humans and animals a state of protection against histamine, this composition being remarkable in particular in that it consists of a mixture of gamma-globulin and histamine.
The gamma-globulin used is extracted from human or animal blood serum. This should of course be a purified preparation corresponding to Cohn's fraction II. It must also be endowed with a sufficient histaminopexic power, greater than or equal to 25, the notion of histaminopexic power and the measure of this power being specified in the following communications from JL Parrot, DA Urquia and C. , Laborde - CRSoc.Biol.
1951, 145, 885 and 1951, 145, 1045.
The histamine used must be in hydrosol ble form and for that purpose salified by a mineral or organic acid, such as
<Desc / Clms Page number 3>
as for example hydrochloric acid or phosphoric acid.
The composition can be presented in a dry state, the two components having been mixed in the dry state or having both been dissolved in saline solution and then the solution evaporated to dryness. It suffices to dissolve this dry product in water to obtain an injectable product. The composition can moreover be presented directly in the form of an injectable solution, such as an isotonic solution.
In order for the effectiveness of the composition to be satisfactory, the constituents must be in determined relative proportions. It is thus, in fact, that if we draw a curve giving the degree of protection with regard to the histamine of the composition as a function of the ratio of histamine to the gamma-globulin, we obtain a bell curve.
This curve can be established by measuring the protective power, with respect to an aerosol of histamine, conferred by the injection into the guinea pig of a cortain volume of this preparation.
This protective action results in the lengthening of the resistance time of the animal to the aerosol. It is measurable in the week following the injection, increases thereafter and is maintained for several months.
Using this test, the following numerical values can be established: for the composition to have satisfactory activity, the histamine (dihydrochloride) gamma-globulin weight ratio should be between 0.003 x 10-3 and 0.05 x 10-3 , .1 maximum activity being observed for a value of this ratio equal to 0.0125 x 10-3. This maximum may vary slightly depending on the dilution of the preparation carried out. If the salifying acid histamine is other than hydrochloric acid, it is naturally necessary to modify the preceding ratio according to the molecular weight of this other acid.
<Desc / Clms Page number 4>
Of course, the invention is not limited to the embodiments described which have only been given as examples.
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
BE563791A true BE563791A (en) |
Family
ID=184899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE563791D BE563791A (en) |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE563791A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0094575A2 (en) * | 1982-05-17 | 1983-11-23 | MCMICHAEL, John | Compositions for treatment of disease states involving immunological factors |
-
0
- BE BE563791D patent/BE563791A/fr unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0094575A2 (en) * | 1982-05-17 | 1983-11-23 | MCMICHAEL, John | Compositions for treatment of disease states involving immunological factors |
EP0094575A3 (en) * | 1982-05-17 | 1984-10-10 | University Patents, Inc. | Methods and materials for treatment of disease states involving immunological factors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU619930B2 (en) | Use of resiniferatoxin and analogues thereof to cause sensory afferent c-fiber and thermoregulatory desensitization | |
DE69933738T2 (en) | Composition containing amino acids and trehalose | |
EP0414608B1 (en) | Cosmetic compositions containing chitosane and glucosamine | |
US20060147405A1 (en) | Method for treating urushiol induced contact dermatitis | |
CA2625804A1 (en) | Pharmaceutical composition based on a morpholinic antimycotic agent and a water-soluble film-forming agent for ungual and periungual application | |
FR2758720A1 (en) | Anti-dandruff composition | |
FR2778562A1 (en) | Compositions containing sea water and basic amino acid inhibit mastocyte activation and basophile degranulation, useful as anti-allergics and anti-inflammatory agents for the skin, eyes, bronchi and nose | |
Khan et al. | The effect of nitric oxide and peroxynitrite on rabbit cavernosal smooth muscle relaxation | |
EP1464330B1 (en) | antiallergic composition containing oligosaccharides in combination with a saponine or a basic aminoacid, for topical administration or for inhalation | |
US5853768A (en) | Topical preparation and method for pain relief | |
Church et al. | Adrenergic and cholinergic activity contributes to the cardiovascular effects of lionfish (Pterois volitans) venom | |
AU9699598A (en) | Novel powder compositions | |
BE563791A (en) | ||
FR2782923A1 (en) | Transforming cosmetic composition into film, for use as face mask, involves mixing composition with at least one alginate salt, and mixing resulting mixture with calcium salt | |
Macrides et al. | Hepatoprotective effects of the shark bile salt 5β-scymnol on acetaminophen-induced liver damage in mice | |
WO1999027902A1 (en) | Composition comprising an amino acid n-undecylenoyl; application in cosmetics | |
EP0768887B1 (en) | Compositions having antiviral properties and preparation process | |
TW200404567A (en) | Stabilised topical formulations containing ketoprofen | |
JPH02196717A (en) | Periodontitis therapy | |
EP1425296B1 (en) | Organic compounds with biological activity as thrombin inhibitors and use thereof | |
EP0618794B1 (en) | Use of 4- (2-oxo-3-bornylidene)methyl]-phenyltrimethylammonium methyl sulphate composition for permanent hair shaping, affording protection from the ravages of the weather, and especially light | |
WO2005094806A1 (en) | Use of quaternary ammonium compounds as specific blockers of transport through aquaporin, compositions comprising the compounds and method of selecting the compounds | |
JP4190216B2 (en) | UV-induced mutation inhibitor and skin external preparation for UV-induced mutation suppression | |
Ay et al. | Effects of androctonus crassicauda scorpion venom on endothelium-dependent and-independent vascular responses of rabbit aorta | |
US20040152682A1 (en) | Stabilized steroid composition and method for its preparation |